Key facts
- Notable investors include Deerfield Management.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Bluefin Biomedicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Bluefin Biomedicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bluefin Biomedicine
Operator of a biotechnology company intended to develop effective antibody-based treatments. The company focuses on the detection of novel cancer antigens and the development of next-generation medicines by researching protein detection methods to interrogate complex tumor specimens and discover differentially expressed cancer antigens, enabling oncologists to treat cancer patients with antibody therapies.
- Sector
- Healthcare
- HQ
- Beverly, MA, United States
- Founded
- 2016
- Website
- bluefinbiomed.com/
- Ownership
- Privately Held (backing)
Bluefin Biomedicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bluefin Biomedicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bluefin Biomedicine in its N-PORT filings yet. We sweep new filings monthly.